companydata.dkCommit Biologics ApS: Financial statements 2023
CVR: 42642649
Commit Biologics ApS (CVR 42642649) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -13,580,251 and a net result of DKK -17,295,813. Equity amounted to DKK 22,578,793. The solvency ratio was 96.8%. The company had 10 employees in the financial year.
- Gross Profit
- -13,580,251 kr.
- Profit/Loss
- -17,295,813 kr.
- Equity
- 22,578,793 kr.
- Total Assets
- 23,325,997 kr.
- Employees
- 10
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of August 24, 2023, Krishna Reddy Polu has joined the board of directors of Commit Biologics ApS.
As of August 24, 2023, Krishna Reddy Polu is registered as adm. dir. of Commit Biologics ApS.
As of August 24, 2023, Nick Stub Laursen has stepped down as director of Commit Biologics ApS.
Commit Biologics ApS has published its interim report for the period September 1, 2021 – December 31, 2022.
As of February 1, 2023, Anker Gunvald Lundemose has joined the board of directors of Commit Biologics ApS.
As of January 31, 2023, KOVSTED & SKOVGÅRD, REVISION & RÅDGIVNING, STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Commit Biologics ApS.
About Commit Biologics ApS
Commit Biologics ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Thomas Lars Andresen. The company's owners include Novo Holdings A/S, Commit Biologics Holding ApS and Bioqube Factory Fund I CommV. In 2025, the company reported a gross profit of DKK -23,365,247 and a net result of DKK -33,781,079 compared with DKK -39,360,775 the year before. Equity amounted to DKK 37,898,027.